Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS113969-01)
Received: 6 July 2020
Accepted: 26 August 2020
First Online: 2 September 2020
Ethics approval and consent to participate
: All authors provide consent for publication.
: JPdRV and RWK are co-founders and managing members of InflamaCORE, LLC, and have licensed patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. JPdRV and RWK are Scientific Advisory Board Members of ZyVersa Therapeutics.